Plus CNSide Cerebrospinal Fluid Tumor Cell Enumeration test gets AMA PLA code

Plus Therapeutics (PSTV) announced that the American Medical Association has approved a new, proprietary laboratory analyses current procedural terminology code for its CNSide Cerebrospinal Fluid Tumor Cell Enumeration test. The dedicated billing code, 0640U, effective July 1, establishes a unique reimbursement identifier for the CNSide CSF TCE test, supporting payer claims processing and facilitating broader clinical adoptions as the company continues the U.S. commercial launch of its CNS metastases diagnostic platform.